Supplementary Figure 4 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Year: 2023
Type: supplementary-materials
Abstract: PDF file, 77K, Comparison of the effect of dacomitinib at 48 hrs and 5 days on cell cycle and apoptosis in BT-474 and SK-BR-3 lines.
Authors: Ondrej Kalous, Dylan Conklin, Amrita J. Desai, Neil A. O'Brien, Charles Ginther, Lee Anderson, David J. Cohen, Carolyn D. Britten, Ian Taylor, James G. Christensen, Dennis J. Slamon, Richard S. Finn
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362533989